Document is current
Any future updates will be listed below
-
Authors
Tsanov, Kaloyan M. https://orcid.org/0000-0001-9007-4844
Barriga, Francisco M. https://orcid.org/0000-0002-0996-7707
Ho, Yu-Jui
Alonso-Curbelo, Direna https://orcid.org/0000-0001-6674-3059
Livshits, Geulah
Tian, Sha
Koche, Richard P. https://orcid.org/0000-0002-6820-5083
Baslan, Timour
Simon, Janelle
Wuest, Alexandra N.
Reyes, José
Park, Jin
Luan, Wei
Wilkinson, John E.
Bhanot, Umesh https://orcid.org/0000-0001-6656-1239
Ray-Kirton, Jordana
Masilionis, Ignas
Dimitrova, Nevenka
Iacobuzio-Donahue, Christine A. https://orcid.org/0000-0002-4672-3023
Chaligné, Ronan https://orcid.org/0000-0003-4332-3291
Pe’er, Dana
Massagué, Joan https://orcid.org/0000-0001-9324-8408
Lowe, Scott W. https://orcid.org/0000-0002-5284-9650
- License Information
-
More Information
Article History
Received: 2 February 2025
Accepted: 19 August 2025
First Online: 25 September 2025
Competing interests
: S.W.L. is a consultant for Fate Therapeutics and is a consultant and holds equity in Blueprint Medicines, ORIC Pharmaceuticals, Mirimus, PMV Pharmaceuticals, Faeth Therapeutics, Selectin Therapeutics and Senescea Therapeutics. R.P.K. is a cofounder of and consultant for Econic Biosciences. R.C. is a consultant for Sanavia Oncology and LevitasBio. D.P. is on the scientific advisory board of Insitro. J.M. holds equity in Scholar Rock. None of these affiliations represent a conflict of interest with respect to the design or execution of this study or interpretation of data presented in this report. The other authors declare no competing interests.
